Symptoms of Protracted Alcohol Withdrawal in Patients with Alcohol Use Disorder: A Comprehensive Systematic Review.
Alcohol withdrawal syndrome
anhedonia
craving
early alcohol withdrawal
protracted alcohol withdrawal
sleep disorder
Journal
Current neuropharmacology
ISSN: 1875-6190
Titre abrégé: Curr Neuropharmacol
Pays: United Arab Emirates
ID NLM: 101157239
Informations de publication
Date de publication:
2023
2023
Historique:
received:
29
10
2021
revised:
31
03
2022
accepted:
29
04
2022
pubmed:
8
7
2022
medline:
4
3
2023
entrez:
7
7
2022
Statut:
ppublish
Résumé
Alcohol withdrawal syndrome (AWS) is characterized by different phases (acute, early and protracted). Protracted alcohol withdrawal (PAW) presents some symptoms, which may persist for several weeks, months or even years after drinking cessation. We conducted a systematic review of the literature in major scientific databases on selected AWS symptoms (craving, sleep disorders, and anhedonia) in patients with alcohol use disorder. Of the 102 eligible publications (70 RCTs and 32 cohort studies), 88 provided data on craving, 21 on sleep disorders, and 1 on anhedonia. Overall, 37 studies assessed craving using the Obsessive Compulsive Drinking Scale (OCDS). Pooled OCDS decreased from 24.2 at baseline to 18.8 at 1 week, 10.3 at 1 month and 9.7 at 3 months. The corresponding estimates for treated individuals were 23.9, 18.8, 8.7, and 8.8, and for non-treated subjects, they were 25.3, 13.9, 13.2, and 11.4, respectively. In 4 studies assessing sleep disorders using the Epworth Sleeping Scale (ESS), the scale remained stable in time, i.e., 7.3 at baseline, 7.3 at 1 week, 7.2 at 1 month, and 7.1 at 3 months. This study confirms the presence of PAW after the resolution of the acute phase of AWS. The pharmacological approach to managing PAW may ensure a more rapid reduction of symptoms in three weeks. We highlight the importance of studying PAW and the ability of pharmacological treatment to reduce its symptoms. This review protocol is registered in Prospero (registration number: CRD42020211265). This systematic review summarizes literature on major symptoms of protracted alcohol withdrawal in patients with alcohol use disorder. The pharmacological approach to manage protracted alcohol withdrawal ensures a more rapid reduction of symptoms (craving in particular), achieving in three weeks similar results obtained only after almost 6 months without treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Alcohol withdrawal syndrome (AWS) is characterized by different phases (acute, early and protracted). Protracted alcohol withdrawal (PAW) presents some symptoms, which may persist for several weeks, months or even years after drinking cessation.
METHODS
METHODS
We conducted a systematic review of the literature in major scientific databases on selected AWS symptoms (craving, sleep disorders, and anhedonia) in patients with alcohol use disorder.
RESULTS
RESULTS
Of the 102 eligible publications (70 RCTs and 32 cohort studies), 88 provided data on craving, 21 on sleep disorders, and 1 on anhedonia. Overall, 37 studies assessed craving using the Obsessive Compulsive Drinking Scale (OCDS). Pooled OCDS decreased from 24.2 at baseline to 18.8 at 1 week, 10.3 at 1 month and 9.7 at 3 months. The corresponding estimates for treated individuals were 23.9, 18.8, 8.7, and 8.8, and for non-treated subjects, they were 25.3, 13.9, 13.2, and 11.4, respectively. In 4 studies assessing sleep disorders using the Epworth Sleeping Scale (ESS), the scale remained stable in time, i.e., 7.3 at baseline, 7.3 at 1 week, 7.2 at 1 month, and 7.1 at 3 months.
CONCLUSION
CONCLUSIONS
This study confirms the presence of PAW after the resolution of the acute phase of AWS. The pharmacological approach to managing PAW may ensure a more rapid reduction of symptoms in three weeks. We highlight the importance of studying PAW and the ability of pharmacological treatment to reduce its symptoms. This review protocol is registered in Prospero (registration number: CRD42020211265).
SUMMARY
CONCLUSIONS
This systematic review summarizes literature on major symptoms of protracted alcohol withdrawal in patients with alcohol use disorder. The pharmacological approach to manage protracted alcohol withdrawal ensures a more rapid reduction of symptoms (craving in particular), achieving in three weeks similar results obtained only after almost 6 months without treatment.
Identifiants
pubmed: 35794766
pii: CN-EPUB-125015
doi: 10.2174/1570159X20666220706105253
pmc: PMC10190151
doi:
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
409-416Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Références
Am Fam Physician. 2004 Mar 15;69(6):1443-50
pubmed: 15053409
Alcohol Res. 2019 Dec 30;40(1):
pubmed: 31886106
Alcohol Clin Exp Res. 1999 Aug;23(8):1289-95
pubmed: 10470970
JAMA Intern Med. 2014 Jan;174(1):70-7
pubmed: 24190578
Intern Emerg Med. 2019 Jan;14(1):143-160
pubmed: 30187438
Alcohol Clin Exp Res. 1999 Oct;23(10):1596-604
pubmed: 10549990
Compr Psychiatry. 2013 Oct;54(7):925-32
pubmed: 23642635
Subst Use Misuse. 2008;43(5):722-32
pubmed: 18393086
Alcohol Alcohol. 2012 Mar-Apr;47(2):133-9
pubmed: 22218671
Alcohol. 1985 May-Jun;2(3):501-5
pubmed: 4026971
Drugs. 2015 Mar;75(4):353-65
pubmed: 25666543
Neuropharmacology. 2017 Aug 1;122:85-99
pubmed: 28108359
Lancet Psychiatry. 2016 Aug;3(8):760-773
pubmed: 27475769
Addict Biol. 2010 Apr;15(2):169-84
pubmed: 20148778
Alcohol Clin Exp Res. 2008 Jun;32(6):1067-73
pubmed: 18445115
J Neuropsychiatry Clin Neurosci. 1997 Summer;9(3):482-97
pubmed: 9276849
Neurosci Biobehav Rev. 2010 Mar;34(4):606-23
pubmed: 19961872
Ann N Y Acad Sci. 2012 Feb;1248:1-17
pubmed: 22172057
Riv Psichiatr. 2018 May-Jun;53(3):154-159
pubmed: 29912218
Drug Alcohol Depend. 2021 Mar 1;220:108536
pubmed: 33503582
Psychopathology. 2018;51(2):130-136
pubmed: 29466805
Alcohol Clin Exp Res. 2021 Jan;45(1):194-203
pubmed: 33119924
Alcohol Res. 2019 Jan 01;40(1):
pubmed: 31649834
J Psychopharmacol. 2020 Nov;34(11):1171-1175
pubmed: 32648800
Alcohol Clin Exp Res. 1985 Dec;9(6):505-12
pubmed: 3911810
Clin Drug Investig. 2014 Jan;34(1):63-80
pubmed: 24307430
Exp Clin Psychopharmacol. 2014 Feb;22(1):43-9
pubmed: 24490710
Alcohol. 2015 Jun;49(4):417-27
pubmed: 25957855
Sleep. 2009 Oct;32(10):1341-52
pubmed: 19848363
J Sleep Res. 2013 Feb;22(1):89-95
pubmed: 22978579
Addict Sci Clin Pract. 2016 Apr 26;11(1):9
pubmed: 27117064
Alcohol Clin Exp Res. 2016 Nov;40(11):2271-2282
pubmed: 27706838
Turk Psikiyatri Derg. 2017 Spring;28(1):51-60
pubmed: 28291298
Heliyon. 2021 Jan 04;7(1):e05868
pubmed: 33458444
Am J Addict. 2010 May-Jun;19(3):238-44
pubmed: 20525030
Subst Use Misuse. 2008;43(3-4):271-84
pubmed: 18365930
Handb Clin Neurol. 2014;125:355-68
pubmed: 25307585
Am J Addict. 2011 Sep-Oct;20(5):435-40
pubmed: 21838842
Neuropsychobiology. 2014;70(2):103-10
pubmed: 25359490
Br J Addict. 1990 Oct;85(10):1253-4
pubmed: 2265284
PLoS One. 2013 Aug 27;8(8):e71560
pubmed: 24013131
Am J Psychiatry. 2001 Mar;158(3):399-404
pubmed: 11229980
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):953-8
pubmed: 21256179